IMP3-saRNA Vaccine in Advanced NSCLC

This is an open-label, single-arm, non-randomized, single-center, prospective phase 1 clinical trial. The study will evaluate the safety, tolerability, and preliminary antitumor activity of IMP3-saRNA (YMN-136) vaccine in patients with advanced non-small cell lung cancer. IMP3-saRNA (YMN-136) is a vaccine product prepared from IMP3 self-amplifying RNA and lipid nanoparticles. The study will enroll patients with histologically or cytologically confirmed non-small cell lung cancer who have failed standard treatment, are intolerant to standard treatment, or have refused standard treatment, and w

Trial Details

NCT ID
NCT07561723
Phase
PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IMP3-saRNA (YMN-136) Vaccine
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Patients aged at least 18 years at screening who voluntarily sign an ethics committee-approved informed consent form before any study procedure and…
  • Patients with histologically or cytologically confirmed non-small cell lung cancer who have failed standard treatment, are intolerant to standard t…
  • Patients with EGFR-sensitive mutations must have failed third-line or later treatment, including failure of at least one EGFR-TKI.
  • Patients with ALK-positive disease must have failed third-line or later treatment, including failure of at least one ALK inhibitor.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →